NCT01891981 - Study of Moxetumomab Pasudotox in Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 17, 2013

Primary Completion Date

April 12, 2017

Study Completion Date

April 12, 2017

Conditions

Leukemia

Interventions

DRUG

Moxetumomab Pasudotox

"Phase I Starting Dose: 30 µg/kg by vein every other day for 6 doses on Days 1, 3, 5, 7, 9, and 11 of each 21-day cycle.~Phase II Starting Dose: Maximum tolerated dose from Phase I."

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston